03 April 2015 | News | By BioSpectrum Bureau
UK based Ergomed opens drug development services centre in Taiwan
Ergomed provides service in clinical development of oncology, immunology and orphan drugs
Singapore: UK-based Ergomed providing specialised services to the pharmaceutical industry and the development of new drugs, has opened a new office in Taiwan for clinical research and consultancy presence in Asia.
Expanding in Asia for the first time, the company has decided to invest in organic growth as a first step. The new subsidiary company in Taipei will act as a hub for business activity across the country and the wider Asian market, ensuring Ergomed is best placed to support existing and new clients working in the region.
Mr Miroslav Reljanovic, CEO, Ergomed commented, "We are very pleased to open an office in Taiwan where there is an expanding life science market. The Taiwan operations are in line with our strategy to expand in Asia through organic growth and acquisitions as stated at our IPO. We are currently working with some exciting Taiwanese companies and the new office gives us the platform to offer our services to pharma and biotech companies in the entire region. It is important for our clients in Taiwan to have local on-the-ground support integrated with an international drug development capability, and we can now provide that very effectively through our Taipei office."
The Taiwan operations will be led by Dr Sy-Shi Wang, the new executive director of global clinical operations, who joined Ergomed in 2014.
Ergomed provides service in clinical development of oncology, immunology and orphan drugs.
Dr Wang said, "Taiwan is a market with tremendous potential and home to some of the world's most progressive, forward-thinking organisations in biopharma development. I am very excited by the opportunity this presents and the foothold it provides Ergomed to expand further our Asian presence."